Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes.
Aged
Body Mass Index
Cardiovascular Diseases
/ diagnosis
Carotid Intima-Media Thickness
Diabetes Mellitus, Type 2
/ complications
Female
Heart Disease Risk Factors
Humans
Hypoglycemic Agents
/ therapeutic use
Insulin
/ therapeutic use
Longitudinal Studies
Male
Metformin
/ therapeutic use
Middle Aged
Predictive Value of Tests
Time Factors
Ageing
Atherosclerosis
Cardiovascular disease
Cardiovascular risk factors
Carotid intima-media thickness
Prediction
Type 2 diabetes
Journal
Journal of diabetes and its complications
ISSN: 1873-460X
Titre abrégé: J Diabetes Complications
Pays: United States
ID NLM: 9204583
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
10
02
2020
revised:
09
06
2020
accepted:
13
07
2020
pubmed:
4
8
2020
medline:
16
11
2021
entrez:
4
8
2020
Statut:
ppublish
Résumé
To investigate measures of carotid intima-media thickness (IMT) and conventional cardiovascular (CV) risk factors as predictors of future carotid IMT, and the prediction of CV events during follow-up based on measures of carotid IMT. Observational longitudinal study including 230 persons with type 2 diabetes (T2D). Mean age at follow-up was 66.7 (SD 8.5) years, 30.5% were women and mean body mass index (BMI) was 31.8 (4.4) kg/m Measures of carotid IMT combined with CV risk factors at baseline predicts attained carotid IMT better than measures of carotid IMT or CV risk factors alone. Carotid IMT did not predict CV events, and the present results do not support the use of carotid IMT as a predictor of CV events in persons with T2D.
Identifiants
pubmed: 32741659
pii: S1056-8727(20)30443-8
doi: 10.1016/j.jdiacomp.2020.107681
pii:
doi:
Substances chimiques
Hypoglycemic Agents
0
Insulin
0
Metformin
9100L32L2N
Types de publication
Journal Article
Multicenter Study
Observational Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107681Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors have completed the ICMJE uniform disclosure form at. www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: the trial received an unrestricted grant from Novo Nordisk A/S for the submitted work. LLC, LT, TPA, AV, TWB, SSL, TJ have reported shares in Novo Nordisk A/S; LLC, LT, TPA, AV, TWB, SSL have reported former employment at Steno Diabetes Center, which is a diabetes hospital and academic institution owned by Novo Nordisk; SSL is employed at Boehringer Ingelheim Pharma GmbH & Co. KG; SSL's contribution was his alone and does not necessarily reflect the official position of Boehringer Ingelheim. AV has received fees from Novo Nordisk and is employed at AstraZeneca A/S; TWB is employed at Novo Nordisk A/S; BT is member of advisory board for Eli Lilly; LB has received fees from and attended advisory for Novo Nordisk A/S; SM has served as a consultant or adviser to: Novartis Pharma, Novo Nordisk, Merck Sharp & Dome, Sanofi-Aventis, AstraZeneca, Johnson & Johnson, Rosche, Mankind, Astra-Zeneca, Boehringer-Ingelheim, Zeeland, E Lilly, Intarcia Therapeutics, Bristol-Meyer Squibb, has received fee for speaking from Novo Nordisk, Merck, Sharp & Dome, Astra-Zeneca, Johnson and Johnson, Rosche, Shering-Ploug, Sanofi-Aventis, Novartis Pharma, E Lilly, Bristol-Meyer Squibb, Boehringer Ingelheim, and has received 2 research grants from Novo Nordisk. The remaining authors declare no conflict of interest.